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Abstract
Pre-clinical models of tumour biology often rely on propagating human tumour cells in a mouse. In order to gain insight
into the alignment of these models to human disease segments or investigate the effects of different therapeutics,
approaches such as PCR or array based expression profiling are often employed despite suffering from biased transcript
coverage, and a requirement for specialist experimental protocols to separate tumour and host signals. Here, we describe a
computational strategy to profile transcript expression in both the tumour and host compartments of pre-clinical xenograft
models from the same RNA sample using RNA-Seq. Key to this strategy is a species-specific mapping approach that removes
the need for manipulation of the RNA population, customised sequencing protocols, or prior knowledge of the species
component ratio. The method demonstrates comparable performance to species-specific RT-qPCR and a standard
microarray platform, and allowed us to quantify gene expression changes in both the tumour and host tissue following
treatment with cediranib, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor, including the
reduction of multiple murine transcripts associated with endothelium or vessels, and an increase in genes associated with
the inflammatory response in response to cediranib. In the human compartment, we observed a robust induction of
hypoxia genes and a reduction in cell cycle associated transcripts. In conclusion, the study establishes that RNA-Seq can be
applied to pre-clinical models to gain deeper understanding of model characteristics and compound mechanism of action,
and to identify both tumour and host biomarkers.
Citation: Bradford JR, Farren M, Powell SJ, Runswick S, Weston SL, et al. (2013) RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by
Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib. PLoS ONE 8(6): e66003. doi:10.1371/journal.pone.0066003
Editor: Rolf Mu¨ller, Philipps University, Germany
Received March 1, 2013; Accepted April 30, 2013; Published June 19, 2013
Copyright:  2013 Bradford et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was funded by AstraZeneca (www.astrazeneca.com) who are current employers of JRB, SJP, SR, SLW, HB, OD, MW, NRS, THC, JRD and STB,
and past employers of MF and NJG. Other than the named authors, the funder had no direct role in study design, data collection and analysis, decision to publish,
and preparation of the manuscript.
Competing Interests: All authors have either a current or past affiliation to the commercial funders of this research (AstraZeneca). This does not alter the
authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: James.Bradford@astrazeneca.com
Introduction
Human tumour xenografts are commonly used to model
response to targeted therapeutics, and the intrinsic or acquired
resistance mechanisms that can limit therapeutic benefit. Growth
of these models is dependent on the interplay between the human
tumour cells and murine stromal cells such as endothelial cells,
leukocytes and fibroblasts recruited to generate a pro-tumour
microenvironment. An ability to differentiate effects on the tumour
and its surrounding tissue is critical to the development of a
clinically relevant understanding of new therapeutic activity. This
is of particular importance when studying agents that impact both
the tumour and stroma. For example, cediranib [1], a potent
vascular endothelial growth factor receptor tyrosine kinase
inhibitor, reduces tumour growth by perturbing tumour-stromal
interactions controlling angiogenesis.
A range of techniques have been used to gain insight into how
the effects mediated by therapeutics deliver anti-tumour efficacy or
to generate broad transcript profiles to assess changes following
treatment. Many of these techniques such as immunohistochem-
istry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA) or
Western blotting based phenotypic or pharmacodynamic mea-
sures are limited to a small number of endpoints, such as direct
target or pathway inhibition, the modulation of cell function such
as proliferation or apoptosis, or changes in cell content. In
contrast, hypothesis free assessments with techniques such as gene
expression arrays are limited by several issues including the
dynamic range of the technologies employed and species specificity
[2–5]. These limitations compromise our ability to confidently
differentiate murine from human transcripts and thereby deter-
mine the dynamic changes within each compartment of a
xenograft tumour upon treatment with therapeutic agents [6].
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Several statistical approaches have been devised to deconvolute
expression in mixed tissue samples from microarray data. These
methods are inherently sensitive to statistical assumptions, and
require either prior knowledge of tissue-specific gene expression
[7], a purified reference for each tissue type [8][9], the proportions
of each tissue type [10][11] or expression data from at least one
tissue type [12][13]. An alternative is to mask human and/or
mouse probe sequences defined as susceptible to cross-species
hybridization prior to gene expression quantification [6][14],
demonstrating that cell type specific gene expression quantification
is possible without prior cell separation although at the expense of
a significant loss of data. Recently, a competitive cross-species
hybridization strategy was devised that can simultaneously
measure gene expression of cancer and host cells from a single
xenograft tissue by hybridizing an un-manipulated RNA sample to
human and mouse arrays under high stringency conditions [15].
The study reported that a combination of the Illumina BeadChip
Expression array platform, specifically designed to minimize
human-mouse cross-species hybridization, and specialist experi-
mental conditions distinguished tumour from host signals with
sufficient specificity and sensitivity. Nevertheless, the approach
remains constrained by inherent limitations in array technology
such as biased transcript coverage and limited dynamic range.
A recent study of orthology between human and mouse at the
exon level revealed that only 7% of exons possess no orthologous
pairings and that these are predominantly located in the UTRs
[16]. However it was also shown that the degree of nucleotide
sequence similarity between the remainder of orthologous exons
varies between 70% and 90% with an average of 85% similarity
[17] suggesting that there is sufficient RNA sequence diversity at
this level to distinguish between the majority of human and mouse
orthologous transcripts.
Sequencing mRNA libraries using second generation sequenc-
ing platforms (RNA-Seq) is emerging as an alternative to
microarrays for genomic analysis of tumours. Sequencing offers
several technical advantages over arrays including greater
sensitivity and dynamic range and the avoidance of probe effects.
In addition to mRNA quantification, sequence data can be used to
detect gene sequence variants including splice isoforms and gene
fusions, as well as somatic mutations [18]. RNA-Seq also offers
unbiased quantification of all expressed genes and is not restricted
to loci targeted specifically by array probesets, therefore increasing
the possibility of quantifying non-protein coding genes such as
lncRNA.
We have devised an RNA-Seq informatics workflow to
simultaneously measure gene expression from tumour and host
tissue from a human xenograft model. By applying a species-
specific mapping strategy we are able to accurately distinguish
RNA originating from human derived cancer cells from the RNA
of murine cells. Our approach does not require prior manipulation
of the RNA population, customized sequencing protocols, specific
experimental conditions, or prior knowledge of the human:mouse
component ratio in the RNA sample. We demonstrate that the
expression values obtained from RNA-Seq in both tumour and
host are comparable with species-specific RT-qPCR. Moreover we
were able to demonstrate the value of this approach to detect
changes in both tumour and host gene expression following
treatment with cediranib.
Results
Species-specific RNA-Seq Workflow
RNA was isolated from four Calu-6 Non-Small Cell Lung
Carcinoma (NSCLC) human xenografts: two untreated, control
(vehicle-only) xenografts (referred to as Control_1 and Control_2),
and two xenografts (referred to as VEGFi_1 and VEGFi_2) from
mice dosed for 4 days with cediranib at 6 mg/kg once daily orally
as previously described [1]. 50 bp reads obtained from the SOLiD
v4 platform (Applied Biosystems) were aligned to the human
(GRCh37/hg19) and mouse (NCBI37/mm9) genomes separately.
To differentiate human and mouse expression it was essential to
remove ,450 K reads mapping to both human and mouse
genomes resulting in loss of yields in each species of 2–2.5% for
human and 17–26% for mouse. The loss of a higher proportion of
mouse genes reflected the lower number of reads mapping to
mouse. Reads that mapped to multiple loci on the same genome
were also removed. A schematic of the species-specific mapping
strategy is shown in Figure 1. Overall, ,16–25 M and ,1.3–
2.0 M reads mapped uniquely to human and mouse respectively
(Table S1), the majority mapping to known transcripts (Table S2)
with most of the protein coding genes featuring at least one
uniquely mappable read (Table S3). Excellent correspondence
(r2=0.92; Figure S1; Table S4) was achieved between the
proportion of reads mapping to mouse and the experimentally
estimated [19] (see Materials and Methods) mouse RNA
composition in the sample which ranged from ,8–17%,
suggesting that the method could serve as an accurate alternative
for measuring the tumour-host content of a xenograft sample and
that the majority of reads are mapped to the correct species.
Comparison of RNA-Seq with RT-qPCR
In order to validate the species-specific gene expression levels
quantified by RNA-Seq, human and mouse specific assays
detecting 170 human and 174 mouse genes (listed in Table S5)
believed to be associated with the interaction between tumour cells
and their microenvironment [19], and therefore expected to show
detectable expression in these samples, were selected for RT-
qPCR TaqManH Profiling on the Fluidigm BioMark System using
the same two control and treated samples analysed by RNA-Seq.
The Fluidigm array was designed to incorporate probes specifi-
cally targeting human or mouse genes [19] and therefore provides
a means to further assess whether reads are mapping to the correct
species. Reproducibility between control biological replicates
observed on both RNA-Seq (Figure S2) and RT-qPCR (Figure
S3) platforms was high. Details of the assay probe identifiers and -
DCT values across both control and treated samples are given in
Table S5.
Using the Control_2 replicate as an example, significant
correspondence was observed in gene expression quantification
across human (r2=0.72; Figure 2A; Table S6A). Despite the low
mouse component in the RNA sample (15%), good correspon-
dence was also achieved in mouse gene expression (r2=0.60;
Figure 2B; Table S6B). Similar levels of correlation (Table S6)
were observed across the Control_1 sample (human: r2=0.69;
mouse: r2=0.59) and two replicates treated with cediranib
VEGFi_1 (human: r2=0.69; mouse: r2=0.56) and VEGFi_2
(human: r2=0.62; mouse: r2=0.56). Correspondence in gene
detection was also high across both species (Table S6). Genes
containing at least one mapped read were classed as detected in
RNA-Seq since this threshold provided high levels of correspon-
dence in both mouse and human (Figure S4). In Control_2, 95%
(144/152) of human genes detected in RNA-Seq (with at least one
mappable read) were also detected in RT-qPCR (Figure 2C).
Conversely, 93% (144/155) of human genes detected in RT-
qPCR were also detected in RNA-Seq. A similar pattern of
correspondence was also observed in the mouse Control_2 sample
in which 97% (139/143) of mouse genes detected in RNA-Seq
Human Tumour Xenograft Profiling Using RNA-Seq
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were also detected in RT-qPCR, and 87% (139/160) detected in
RT-qPCR were also detected in RNA-Seq (Figure 2D).
Of the 174 mouse genes, 13 genes were classed as differentially
expressed (|log2 fold change|.1, p-value ,0.05) in response to
Figure 1. Schematic of the species-specific mapping workflow applicable to RNA-Seq data from xenografts. (1) Human tumour cells
originating from the Calu-6 non-small cell lung carcinoma cell line were grown in mouse, and RNA extracted and sequenced using standard
protocols. (2) Sequenced reads were then mapped to human and mouse genomes separately, and reads mapping to both species discarded. The
remaining reads were used to quantify and delineate tumour (human) from host (mouse) gene expression.
doi:10.1371/journal.pone.0066003.g001
Figure 2. RNA-Seq gene quantification and detection closely corresponds to values obtained by species-specific RT-qPCR.
Comparison between RNA-Seq and RT-qPCR across 170 human and 174 mouse genes from a Calu-6 human xenograft sample (Control_2). Correlation
in gene expression in (A) human (r2= 0.72) and (B) mouse (r2=0.60). r2 values are calculated only from genes detected on both platforms. Overlap in
number of (C) human and (D) mouse genes detected in both RNA-Seq and RT-qPCR, and genes detected on one platform only. The transcript
mapped to by the highest number of reads was chosen to represent the expression of its parent gene. Any gene containing at least one mappable
read was classed as detected in RNA-Seq. The genes included in this comparison are listed in Table S5. Details of gene expression and detection
correspondence across both Control_1 and Control_2 samples are given in Table S8.
doi:10.1371/journal.pone.0066003.g002
Human Tumour Xenograft Profiling Using RNA-Seq
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e66003
cediranib by RNA-Seq using the two control and two treated
samples. In order to validate these, we performed RT-qPCR on an
additional four treated and six control samples. DCT values for all
six treated and eight control samples are given in Table S7. Table 1
indicates that 8/13 genes classed as differentially expressed by
RNA-Seq were validated by RT-qPCR (|log2 fold change|
.0.50, p-value,0.05). Of these, there was strong agreement (RT-
qPCR |log2 fold change| .1.00, p,0.05) between platforms for
four of these genes (Flt1, Kdr, Dll4, Il1b). These results suggest that
RNA-Seq shows rich potential as a robust platform to measure
mouse gene expression changes from xenograft samples even at
low coverage and with low numbers of replicates.
Comparison of RNA-Seq with Human and Mouse Gene
Expression Microarrays
The same two control RNA samples analysed by RNA-Seq
were hybridised to Affymetrix Human U133 Plus 2.0 and
Affymetrix Mouse 430 2.0 gene arrays. The majority of probes
on these arrays have been designed to target the 39 un-translated
region (39UTR) of a gene, which is typically divergent between
even highly conserved ortho- and parologues [16]. This maximizes
the probability of delineating expression of genes from different
species making it the most appropriate standard array technology
to perform species-restricted expression measurements.
Overall, good correspondence was achieved between RNA-Seq
and microarray quantified human gene expression values
(r2=0.46–0.50; Figure 3A; Table S8A). Lower correspondence
was observed between mouse genes (r2=0.32–0.35; Figure 3B;
Table S8B) possibly due to the low mouse content of xenograft
samples either increasing the susceptibility of the mouse array to
cross-species contamination from human transcripts or reducing
the ability of both platforms to quantify host expression accurately.
To test the contribution of the former and estimate the impact of
cross-species hybridization we identified probes at high risk of
cross-species signal, defined as those with up to three mismatches
to the transcriptome of the alternative species [14]. High risk
human gene expression correspondence was consistently lower
(mean Dr2=20.11; Figure 3C, Table S8A) than low risk
correspondence. This decrease was more marked on the mouse
array (mean Dr2=20.18; Figure 3D, Table S8B) suggesting that,
whilst cross-species hybridization is an issue on both the human
and mouse arrays, more of an effect is observed on arrays designed
for the smaller species component, possibly due to greater
competition from the larger component for high risk probes.
RNA-Seq Differentiates Two Different Xenograft Models
To assess further the ability of RNA-Seq to distinguish tumour
from host signals, we performed a second RNA-Seq analysis on
samples from two untreated LoVo colorectal adenocarcinoma
human xenografts. Mapping statistics similar to those from the
Calu6 model were achieved and these are summarized in Table
S9. We compared relative human and mouse gene expression
levels between the Calu6 (lung) and LoVo (colon) models,
hypothesizing that the majority of the expression changes would
be observed between tumour rather than host genes. 4219 tumour
genes were differentially expressed (log2 fold change magnitude
.1.5, p,0.001) between Calu6 and LoVo compared to only 140
host genes. Genes over-expressed in LoVo were significantly
enriched for associations with colorectal cancer (IPA
p=5.74610214) corresponding to the LoVo tumour type.
In-silico Functional Enrichment Analysis of the Tumour-
host Specific Response to Cediranib
We next investigated whether differentially expressed genes
identified from the RNA-Seq approach reflect known biology
associated with the response to the VEGF-signaling inhibitor
cediranib. Cediranib is a small molecule inhibitor of VEGF-R1, 2,
and 3 with additional activity versus c-kit [1] [20] and to a lesser
extent PDGFR [20]. Treating tumour xenografts with cediranib
inhibits tumour growth by preventing angiogenesis and inducing a
regression of immature vasculature within the tumour [1] [21],
therefore cediranib has little effect in cell culture. As a result of the
changes in the vasculature, genes associated with vessels would be
predicted to be reduced, and genes associated with cellular stress
associated feedback loops induced.
Using the two Calu-6 human lung tumour xenografts from
animals treated with cediranib, both tumour and host gene
expression changes between control and treated samples were
measured using DESeq [22]. For the purpose of the functional
analysis, significantly differentially expressed genes were defined as
those achieving fold change magnitude.2 and p-value,0.1,
resulting in 271 up-regulated and 771 down-regulated tumour
genes in response to cediranib, and 192 up-regulated and 861
down-regulated host genes. Read counts across each human and
mouse transcript for the two treated and two control samples are
given in Tables S10 and S11 respectively. Fold changes and
significance for the same transcripts are given in Tables S12
(human) and S13 (mouse). Included in these lists are a number of
non-protein coding transcripts such as lncRNAs potentially
involved in the response to cediranib and these are also indicated
in Tables S12 and S13. Of the 271 up-regulated tumour genes,
only 10 overlapped with a corresponding up-regulated host gene.
Similarly only 52 down-regulated tumour genes overlapped with a
corresponding down-regulated host gene, further highlighting the
ability of the RNA-Seq approach to differentiate species-specific
gene changes.
A survey of the list reveals a reduction in a number of host
transcripts associated with endothelial cells or vasculature,
consistent with the mode of action of cediranib. In addition to
detecting a reduction in well described genes such as Vegfr-2 (Kdr;
Table 1. RT-qPCR validation of mouse gene expression
changes in response to cediranib identified by RNA-Seq.
RNA-Seq RT-qPCR
Gene log2 FC p-value log2 FC p-value Agreement
1
Vegfa 2.49 6.06E-05 0.95 4.28E-02 **
Mmp9 2.42 4.60E-04 0.36 6.64E-01 *
Flt1 21.65 8.54E-04 21.11 1.68E-06 ***
Gpr116 21.30 2.85E-03 20.61 1.02E-04 **
Serpine2 21.06 7.61E-03 0.30 7.59E-01 NA
Tie1 21.42 7.99E-03 20.70 1.03E-02 **
Kdr 21.21 8.08E-03 21.25 7.98E-06 ***
Tek 213.73 1.66E-02 20.46 9.44E-02 **
Eng 21.08 2.58E-02 20.32 4.70E-01 *
Dll4 22.84 3.40E-02 21.67 1.27E-02 ***
Il1b 1.23 3.69E-02 1.29 3.53E-02 ***
Serpineb5 3.46 3.73E-02 20.20 8.94E-01 NA
Pecam1 21.02 4.13E-02 20.20 5.02E-01 *
1***Strong agreement (RT-qPCR |log2FC|.1 and p-value,0.05),
**agreement (RT-qPCR |log2FC|.0.50 and p-value,0.05),
*some agreement (fold change in same direction), NA no agreement.
doi:10.1371/journal.pone.0066003.t001
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log2 fold change=21.21, p=0.008) and Dll4 (log2 fold
change =22.84, p=0.03), a reduction in less well studied genes
such as the Clec14a (log2 fold change=21.77, p=0.01), a tumour
specific endothelial gene that regulates pro-angiogenic phenotypes
[23], was also detected. Reduction in endothelial genes was
associated with a concomitant up-regulation of murine genes
associated with inflammation, stress response, and cell migration.
An inflammatory response induced by inhibition of VEGF-
signalling, and the subsequent recruitment of bone marrow
derived cells such as CD11b+ Gr-1+ myeloid cells to the tumour
microenvironment has been described as a resistance mechanism
for VEGF-signaling inhibitors [24–26]. Although this is thought to
be mediated by Bv8 and Gcsf, a number of other inflammation
genes such as Ptgs2 (log2 fold change= 1.54, p=0.0001) and Il1b
(log2 fold change= 1.23, p=0.04) were up-regulated, which may
also function to recruit inflammatory cells or bone marrow derived
cells to the tumour following treatment. The RNA-Seq analysis
also revealed novel murine genes induced following cediranib
treatment. One notable gene induced on treatment is S100a9
recently shown to drive inflammatory cell mediated chemo-
resistance in mouse syngeneic models [27].
Functional enrichment amongst genes showing significantly
differential expression on cediranib treatment was assessed using
IPA (IngenuityH Systems, www.ingenuity.com). A threshold-free
approach was also taken to assess functional enrichment using
Gene Set Enrichment Analysis (GSEA, http://www.broad.mit.
edu/gsea/index.jsp) [28], with genes ordered by –log10(p-
value)6N where N=1 for genes up-regulated in response to
cediranib, and N=21 for down-regulated genes.
Figure 3. RNA-Seq versus microarray gene expression correspondence. Comparison between RNA-Seq and microarray platforms across
8621 human and 5467 mouse genes from a Calu-6 human xenograft sample (Control_2) and detected on both platforms. Correlation in gene
expression in (A) human (r2=0.50) and (B) mouse (r2=0.35). r2 values are calculated only from genes detected on both platforms. The transcript
mapped by the highest number of reads was chosen to represent the expression of its parent gene. Any gene containing at least one mappable read
was classed as detected in RNA-Seq. A gene was called ‘‘present’’ on the array if the signals of all probesets assigned unambiguously to that gene
were separable from the general background with a p-value,0.01. Correlation increases between (C) human and (D) mouse gene expression values
across both samples when probes on the array at high risk of cross-species hybridization are removed. Only genes detected on both platforms were
considered. A mean of ,8400 human and ,5300 mouse genes were used in the comparison of which ,6800 and ,4400 genes were deemed at
high risk respectively. Genes at high risk were defined as those corresponding to a probe with up to three mismatches to the transcriptome of the
alternative species.
doi:10.1371/journal.pone.0066003.g003
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GSEA revealed significant enrichment (GSEA p,0.001) of
several hypoxia associated signatures in human tumour genes
differentially regulated in response to cediranib (Figure 4A).
Specifically, tumour genes up-regulated in response to cediranib
were enriched with genes up-regulated in hypoxia, and vice versa
(Figure 4B), including increased expression of glycolysis pathway
genes and decreased expression of genes involved in oxidative
phosphorylation. IPA analyses supported these findings, indicating
an up-regulation of genes under the control of the transcription
factors EPAS1 (IPA p=4.1961024) and HIF1A (IPA
p=6.7461024), both of which are induced upon hypoxia, with a
simultaneous down-regulation of genes involved in nitric oxide
and reactive oxygen species production (IPA p=2.0661024).
Tumour genes down-regulated following cediranib treatment were
strongly enriched for genes defined by the Gene Ontology [29] to
be involved in the cell cycle consistent with the reduction in
tumour growth (IPA p=2.5461025; Figures 4C and 4D). In
addition potential targets of the E2F transcription factor family
were also modulated (IPA p=4.1461024) consistent with an anti-
proliferative effect in the tumour.
IPA analysis revealed an up-regulation of genes involved in the
inflammatory response (IPA p=1.1561029), in particular leuko-
cyte and phagocyte activation/migration (Figure 4E), supporting
the finding by GSEA that genes associated with cytokine activity
are increased following cediranib treatment (GSEA p,0.001). Up-
regulation was also observed from genes associated with the
transcription factor NFKB (IPA p=3.5761027). Down-regulation
was observed for host genes involved in blood vessel development
(IPA p=1.2061026), angiogenesis (IPA p=2.3261026), vasculo-
genesis (IPA p=9.6761026) and migration of endothelial cells
(IPA p=2.6961026; Figure 4E) coupled with reduced expression
of genes involved in collagen connective tissue formation (GSEA
p,0.001). GSEA also revealed a related to the down-regulation of
endothelial genes. As in the human cells, the mouse compartment
also showed down-regulation of genes involved in the cell cycle
(IPA p=1.0261027) and DNA repair pathways (IPA
p=5.4161026) following cediranib treatment. Thus, differentially
expressed host genes showed clear enrichment for functions
associated with the roles of VEGF in the cell. Immunohistochem-
ical analysis confirmed the reduction of the supporting vasculature
in cediranib treated tumours (Figure 5), which suggests that the
broad pathway changes identified by RNA-Seq are translated into
phenotypic effects.
Discussion
Using current transcript based approaches to differentiate
murine from human transcripts in human tumour xenografts
and thus investigate the effects of therapeutic agents, or identify
emerging resistance mechanisms that potentially limit efficacy has
proven challenging. Standard microarray approaches are limited
by their susceptibility to cross-species contamination, low dynamic
range and biased transcript coverage. PCR based approaches offer
an increase in dynamic range, but are limited to a fraction of the
transcriptome even with new high-throughput techniques. In this
study, we have demonstrated the application of RNA-Seq to
xenograft profiling and its potential in differentiating the tumour
and host components on a single platform. We show that RNA-
Seq is highly comparable to a gold standard approach such as RT-
qPCR in measuring species-specific transcriptional profiles, and
that a simple adaptation to the standard mapping pipeline is
sufficient to accurately quantify tumour and host specific gene
expression. Whilst bias towards highly expressed mouse genes in
our selection of transcripts for RT-qPCR profiling may have
contributed to the high correspondence between the two
platforms, our results strongly suggest that the approach will
accurately measure the expression levels of low abundance
transcripts given sufficient sequencing depth. A major technical
challenge of profiling the mouse component of a tumour xenograft
is the often high tumour content of the sample where a 10:1 ratio
of human to mouse RNA is typical. Therefore, we were
encouraged by the high level of correspondence between RNA-
Seq and RT-qPCR across mouse genes despite low sequencing
depth and a significant percentage of potential mouse sequences
lost as a result of cross-mapping to the human genome.
Furthermore, meaningful separation of tumour and host gene
changes upon cediranib treatment was achieved and RNA-Seq
suggested a stromal response to the VEGF signaling inhibitor.
However, since the mouse component typically consists of a mixed
cell population, it is challenging to attribute mouse gene expression
to stromal cells specifically. Higher coverage and longer read
lengths are likely to yield more accurate results, greater species
specificity and increase the possibility of detected splice variants,
mutations and gene fusions in the host tissue, in addition to novel
non-coding mouse RNA expression changes upon treatment
However, despite rapid technological developments and decreas-
ing costs of sequencing, low mouse coverage is likely to remain an
issue for some time therefore our finding that valid information
from the host can be sought even below recommended levels of
sequencing depth is significant. Cost implications also continue to
hinder the use of large numbers of replicates in RNA-Seq so we
were further encouraged that using only two treated and two
control animals generated relevant hypotheses. However, in
general, we recommend that hypotheses generated from such
low replicate numbers are subsequently validated with lower cost
technologies and additional replicates to increase the likelihood of
capturing the full extent of technical and biological variability.
Recently, a statistical method to pre-assign short reads to their
species of origin prior to mapping has been proposed [30]. The
study reports that whilst the method yields an improvement over
standard mapping tool assignment, the proportion of reads
misclassified by the latter is small, supporting our conclusion that
by simply using the read classification implied from a standard
mapping tool such as Bowtie [31], RNA-Seq can accurately
differentiate tumour and host transcription. Our study also goes
further by being the first to demonstrate that potentially relevant
biology may be extracted from the mouse component, even at low
sequencing depth, exemplified by accurate differentiation of the
tumour/host response to cediranib.
The level of correspondence between RNA-Seq and the 39
mRNA arrays representing both species suggests that the platforms
show comparable performance in quantifying expression across
both human and mouse transcripts. However, correspondence
between RNA-Seq and the mouse array increased significantly
when probes at risk of cross-hybridization were ignored suggesting
that cross-species contamination is an issue on the gene array
particularly across genes from the species representing the smaller
RNA component. Nevertheless, arrays remain viable tools for
genomic studies including the analysis of samples derived from
xenografted tissues, particularly with the development of platforms
such as the Illumina BeadChip Expression Array designed
specifically to minimize cross-species hybridization [6][15].
Whilst findings should be validated using larger sample numbers
and lower throughput technologies such as PCR or Western
Blotting, we believe the combination of RNA-Seq profiling and
pathway mapping can generate rational hypotheses from both the
tumour and host into the effect of treating tumours with drugs.
Using cediranib as an example, reduction in a number of host
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Figure 4. RNA-Seq differentiates the tumour (human) transcriptional response to cediranib from the host (mouse). Gene Set
Enrichment Analysis (GSEA) reveals significant enrichment of (A) hypoxia and (B) cell cycle associated signatures in tumour genes differentially
regulated in response to cediranib dosed at 6 mg/kg once daily for 4 days (** indicates gene sets enriched with p,0.001, FDR q,0.05 and FWER
p,0.1; * indicates gene sets enriched with p,0.001 and FDR q,0.05). GSEA-defined ‘‘Leading Edge’’ genes most frequently included in (C) hypoxia-
associated gene sets and up-regulated in response to cediranib include CA9, HK2 and VEGFA. Leading edge cell cycle associated genes are given in
(D). (E) Ingenuity Pathway Analysis (IPA) highlights functions significantly enriched (p,161025) amongst host genes differentially regulated in
response to cediranib. For both GSEA and IPA, genes achieving a log2 fold change magnitude.1 and p,0.1 were defined as differentially regulated.
n= 2 in treated and control groups; a positive fold change indicates genes up-regulated in response to cediranib, and vice versa.
doi:10.1371/journal.pone.0066003.g004
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transcripts associated with endothelial cells or vasculature was
observed, consistent with the mode of action of cediranib. In
additional, RNA-Seq revealed a number of novel host genes such
as Clec14a and S100a9, as well non-protein coding transcripts such
as lncRNAs potentially involved in the cediranib response. Further
exploration of the host genes modified by cediranib will give
broader insight into the types of vessels targetted, and more
importantly the feedback loops induced following treatment. In
conclusion, this study has shown that RNA-Seq is an effective
strategy to generate hypotheses into both the mode of action,
highlighting potential biomarkers of drug target inhibition, as well
as induced responses following drug treatment.
Materials and Methods
Ethics Statement
Tumour xenograft tissue was derived from experiments
conducted with strict adherence to licenses issued under the UK
Animals (Scientific Procedures) Act 1986 and after local ethical
review and approval. The study was performed under Home
Office project license (PPL) number 40/3483.
Tumour Xenograft Establishment and
Immunohistochemistry
Cells for tumour implantation were grown in DMEM supple-
mented with glutamine and 10% foetal calf serum and implanted
subcutaneously in nude mice as previously described [1]. Calu-6
xenografts were established in fourteen mice and eight animals
dosed for 4 days with cediranib at 6 mg/kg once daily orally once
tumours reached 0.2 cm3, and six animals with 1% polysorbate 80
vehicle alone as previously described [1]. Two control LoVo
xenografts were also established subcutaneously and animals dosed
with 1% polysorbate 80 vehicle. All control tumours were grown
to between 0.8 and 1 cm3 then rapidly excised and snap frozen in
liquid nitrogen. CD31 immunohistochemical staining and micro-
vessel density analysis on the fourteen Calu-6 xenografts was
performed as described in [32]. Two treated xenografts with the
lowest microvessel density and two control xenografts with the
highest microvessel density were selected for RNA-Seq with the
purpose of method testing and evaluation.
RNA Extraction
,50 mg of tissue were cut from the frozen tumours and RNA
isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen)
according to manufacturer’s instructions. On-column DNase
digestion was performed using the RNase-free DNase Kit
(Qiagen). RNA concentration was measured using the NanoDrop
ND1000 (NanoDrop), and quality determined using the Agilent
RNA nano 6000 kit and Bioanalyzer (Agilent Technologies). RNA
integrity numbers (RIN) for all samples fell between 7 and 10.
Human-specific and Mouse-specific TaqManH Fluidigm
Profiling
Human and mouse specific TaqMan Gene Expression Assays
were designed and supplied by Applied Biosystems, and eukaryotic
18S rRNA was used as the endogenous control. Each of the assays
was validated for species specificity by cross screening versus both
a human and mouse mRNA reference library containing the
combined mRNA context of 10 human and mouse cell lines [19].
Reverse transcription was performed with 50 ng of total RNA in a
final volume of 20 ml, using the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems). The following thermal
profile was used: 25uC for 10 minutes, 37uC for 120 minutes, 85uC
for 5 seconds and 4uC for 2 minutes. Pre-amplification was
performed with 1.25 ml of resulting cDNA in a final volume of
5 ml, using a pool of TaqMan assays at a final dilution of 1 in 100
and TaqMan PreAmp Master Mix (Applied Biosystems). The
following thermal profile was used: 95uC for 10 minutes, 14 cycles
of 95uC for 15 seconds and 60uC for 4 minutes. Pre-amplified
samples were diluted 1 in 5 with TE prior to performing qPCR on
the Fluidigm BioMark System.
Sample and assay preparation for 48.48 Fluidigm Dynamic
Arrays were performed according to manufacturer’s instructions.
Briefly, samples were mixed with DA Sample Loading Reagent
(Fluidigm), and TaqMan Gene Expression Master Mix (Applied
Biosystems). Assays were mixed with DA Assay Loading Reagent
(Fluidigm). The 48.48 Fluidigm Dynamic Arrays were primed and
Figure 5. The phenotypic effects of cediranib observed by immunohistochemical analysis of supporting vasculature in cediranib
treated tumours. Calu-6 xenografts were established and dosed for 4 days with cediranib at 6mg/kg once daily and fixed in formalin. Micro Vessel
Density was then quantified by histological staining for CD31 as previously described [32]. Images are representative for CD31 staining in control and
cediranib treated tumours, and arrows indicate blood vessels. Graph depicts the significant (p-value,0.001; student t-test) reduction of the
supporting vasculature in cediranib treated tumours; 8 control tumours and 6 cediranib tumours, error bars are standard error of the mean.
doi:10.1371/journal.pone.0066003.g005
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loaded on an IFC Controller (Fluidigm) and qPCR was performed
on a BioMark System (Fluidigm) using the following thermal
profile: 50uC for 2 minutes, 95uC for 10 minutes and 40 cycles of
95uC for 15 seconds and 60uC for 1 minute. Data were collected
and analysed using the Fluidigm BioMark Real-Time PCR
Analysis software.
Species-specific normalisation of the expression data to 18S
rRNA was achieved by correcting the eukaryotic 18S rRNA Ct
values measured using TaqMan assay Hs99999901_s1 (Applied
Biosytems) for the proportion of human and mouse 18S rRNA in
each xenograft sample [19]. Gene expression values were
calculated using the comparative CT (2DCT) method as
previously described in User Bulletin #2 ABI PRISM 7700
Sequence Detection System 10/2001, using the corrected 18S
rRNA Ct values for normalisation. Genes altered by cediranib
treatment were determined by student t-tests.
Experimental Estimation of Species Content of Sample
The proportions of human and mouse 18S rRNA were
determined using species-specific ARMSTM TaqMan RT-qPCR
assays designed in-house. Human and mouse 18S rRNA ARMS
assay primer and probe sequences are given in Table S14. Reverse
transcription was performed with 1 ng total RNA in a final volume
of 50 ml using the in-house 18S rRNA reverse primer which reacts
with both human and mouse sequence at a final concentration of
0.5 mM and the TaqMan Reverse Transcription Kit (Applied
Biosystems). The reaction was performed on the ABI PRISM 7700
Sequence Detection System (Applied Biosystems) using the
following thermal profile: 25uC for 10 minutes, 48uC for 30
minutes, 95uC for 5 minutes and 4uC for 2 minutes. qPCR was
performed with 5 ml resulting cDNA in a final volume of 25 ml
using the in-house, species-specific 18S rRNA ARMS assays at a
final concentration of 0.2 mM each primer and 0.1 mM probe and
TaqMan Universal PCR Master Mix (Applied Biosystems). The
PCR was performed on the ABI PRISM 7700 Sequence Detection
System (Applied Biosystems) using the following thermal profile:
50uC for 10 minutes, 94uC for 20 minutes, and 40 cycles of 95uC
for 20 seconds and 60uC for 1 minute.
Human and Mouse Genomic DNA (Promega) and Human and
Mouse Universal Reference RNA (Stratagene) were used to
confirm assay specificity. Standard curves, generated using
Human and Mouse QPCR Reference Total RNA (Stratagene),
were used to determine the proportions of human and mouse 18S
rRNA in each xenograft sample. This method was validated by
determining the relative amounts of human and mouse 18S rRNA
in known synthetic mixtures of human and mouse Total RNA.
Predictions correlated closely with the known values (r2 = 0.99).
The Ct value obtained for each xenograft sample from the
eukaryotic 18S rRNA assay Hs99999901_s1 was corrected for the
proportion of human and mouse 18S rRNA present by dividing
this Ct value by the proportion on the linear scale.
RNA Library Preparation for Sequencing
Total RNA was further cleaned using the Ribominus concen-
tration module (Invitrogen) according to manufacturer’s instruc-
tions. rRNA depletion was carried out with the Dynabeads mRNA
purification kit (Invitrogen) according to manufacturer’s instruc-
tions. Successful removal of rRNA was confirmed using the
Bioanalyzer. Libraries enriched with polyA mRNA suitable for
sequencing by the SOLiD platform were created using the SOLiD
Total RNA Seq Kit supplied by Applied Biosystems in combina-
tion with the SOLiD RNA Barcoding Kit, Module 1–16. In each
instance, RNase III digested polyA RNA was used as input into
library creation and 15 cycles of amplification were employed to
produce the final libraries. These libraries were sequenced on the
SOLiD platform (Applied Biosystems). Initially, sequencing of the
10 bp library barcode was performed followed by 35 bp reverse
and 50 bp forward paired-end sequencing. Only the 50 bp
forward reads were used in this study.
Microarray Preparation and Data Analysis
100 ng of RNA was hybridised on both the Affymetrix
GeneChip U133 Plus 2 and Mouse Genome 430 2.0 GeneChipsH
with 39 IVT Express Labeling Kits. All microarray procedures
were performed at AROS, Denmark following manufacturer
instructions. Robust Multi-array Average (RMA) normalization on
the raw CEL files was carried out using the R Bioconductor
package ‘‘affy’’ [33]. Probeset to gene level mappings and gene
expression summarization were performed using the R Biocon-
ductor package ‘‘xmapcore’’ [34].
In order to identify the Human U133 Plus 2.0 probesets most
susceptible to cross-hybridisation from mouse mRNA, we
performed similarity searches between all oligonucleotide 25-mer
probe sequences and the mouse transcriptome as defined by
Ensembl version 63 using Bowtie [31] in -v alignment mode with a
tolerance of 3 mismatches. The whole procedure was then
repeated for Mouse 430 2.0 array probesets against the human
transcriptome. All genes mapped by probesets containing probe
‘‘hits’’ were defined as susceptible to cross-species signals. 92,108/
496,468 mouse array probes (18.6%) mapped to the human
transcriptome with at least 3 mismatches corresponding to
21,953/45,101 (48.7%) probesets and 13,245/18,109 (73.1%)
genes. 109,075/604,258 human array probes mapped to the
mouse transcriptome corresponding to 24,448/54,675 (44.7%)
probesets and 14,282/20,808 (68.6%) genes.
Species-specific Genome Alignment and Annotation
Reads of length 50 bases were aligned to the human (GRCh37/
hg19) and mouse (NCBI37/mm9) genomes separately using
Bowtie [31] in -n alignment mode. In both cases, reads were also
mapped to a species-specific exon junction database simultaneous-
ly with the genome (see below). Seed length was set to 25 bases
with no more than 2 mismatches allowed in this region. The first
and last bases were ignored as they are supported by only one
colour, and five bases were trimmed from the low quality 39 end of
each read giving an effective read length of 43 bases. The
‘‘tryhard’’ parameter was set to ‘‘true’’, and only uniquely mapped
reads were considered so the -m option was set to 1. All other
parameters were set to their defaults. A custom Perl script was used
to remove reads that mapped to both human and mouse genomes.
To avoid ambiguous assignment of intron-spanning reads to
pseudogenes [35], we mapped reads simultaneously across the
genome and a species-specific splice junction database, thus reads
mapping to both a pseudogene and splice junction were classed as
a non-uniquely mappable and discarded. Non-redundant datasets
of 336,102 and 248,958 known human and mouse exon-exon
junctions respectively were generated using exon coordinates
downloaded from Ensembl version 63. To ensure that a 43 base
read overlapped a splice junction, only the last 42 bases of the first
exon and the first 42 bases of the second exon were considered (if
the exon length exceeded 42 bases). An additional ,6% (,1.2 M
reads) and ,8% (,150 K reads) of reads mapped in the sense
orientation to our human and mouse splice junction datasets
respectively (Table S15). Of these hits, only ,0.01% (,150 reads)
and 0.04% (,70 reads) mapped in the antisense direction and
were discarded as they were considered false positive hits. Raw
sequence data are available in the ArrayExpress database (www.
ebi.ac.uk/arrayexpress) under accession number E-MTAB-1627.
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Measurement of Expression Level
Bowtie alignment format was converted to BED format using a
custom Perl script, and the intersectBed tool from the BEDtools
suite of software was used to overlap the mapped reads with.gtf
annotation files based on Ensembl version 63. From the overlap
files, the number of reads mapping to each Ensembl transcript was
calculated. We adapted the RPKM measure of [36] to calculate a
normalized expression level based on the read count across the
transcript:
RPKM~C
N
T(L{U)
ð1Þ
where N is the number of reads mapping to the region, L is the
region length, U is the number of non-unique loci across the
transcript (see below), T corresponds to the total number of
uniquely mappable reads in each cell line, and C is a constant set
to 16106 in this study. To avoid taking logs of zero, we added a
small constant (0.001) to the RPKM.
Non-unique Loci Identification
There are a significant number of positions where, for a given
50-base sequence, one or more identical 50-mers are found
elsewhere on the genome. At these loci, the probability of finding a
uniquely-mapped read given our mismatch criteria is lower than at
other positions, possibly preventing the detection of expression at
these sites. Whilst attempts have been made to record the
‘‘uniqueome’’ of individual species [37], a combined human-
mouse uniqueome applicable to xenograft RNA-Seq is lacking.
Therefore, we generated our own in-house dataset by performing
an exhaustive all-against-all search for all non-unique 50-mers
across a concatenated human-mouse genome and recorded where
they matched against the reference. In detail, starting from each
base position on a chromosome we took a 50 base region of
consecutive sequence and searched for an identical 50 base match
elsewhere on the concatenated genome. If one or more matches
were found then that base position and all start positions of the
matches were marked with a ‘‘1’’, otherwise the base position was
marked with ‘‘0’’. In this way, a profile of ‘‘ones’’ (corresponding to
non-unique loci) and zeros (unique-loci) was a generated for each
chromosome in human and mouse. 15% and 18% of human and
mouse genomic loci respectively were defined as non-unique using
these criteria.
Differential Expression in RNA-Seq
We used the R Bioconductor package DESeq [22] to identify
genes differentially expressed between cediranib treated and
control samples. DESeq uses a model based on the negative
binomial distribution, a generalisation of the Poisson model that
allows modelling of biological as well as technical variance. Count
data were uploaded into the R session in the form of a tab-
delimited table with five columns with the first column indicating
gene identity, and the others representing reads counts in
Control_1, Control_2, VEGFi_1 and VEGFi_2. Size factors
(effective library sizes) were calculated by dividing the library size
of each sample by the median library size of all four samples. All
other DESeq package functions were applied using default
parameters.
Correspondence Score
To measure detection correspondence between RNA-Seq and
RT-qPCR we used a modified version of the Matthew’s
Correlation Coefficient to calculate a correspondence score, CS
[38–39]
CS~
(A|B){(C|D)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(AzC)(AzD)(BzC)(BzD)
p ð2Þ
where A indicates the number of genes detected on both platforms,
B indicates the number of genes undetected on both platforms, C
indicates the number of genes detected by RNA-Seq but
undetected by RT-qPCR, and D indicates the number of genes
undetected by RNA-Seq but detected by RT-qPCR. A CS of -1
means that all genes detected by RNA-Seq are undetected by RT-
qPCR and vice versa, a CS of zero means that correspondence is
no better than random, and a CS of 1 indicates perfect
correspondence.
Supporting Information
Figure S1 Strong correlation between RNA-Seq versus
experimentally determined species content of RNA
sample. For RNA-Seq, percentages are based on the proportion
of reads mapping uniquely to mouse. Experimental procedure for
confirming species content is given in Materials and Methods.
(TIFF)
Figure S2 RNA-Seq gene expression correspondence
between biological replicates. Scatterplots (A) and (B)
represent tumour (human) gene expression from control
(r2=0.93) and cediranib treated (once daily orally at 6 mg/kg;
r2=0.90) animals respectively. Scatterplots (C) and (D) represent
host (mouse) gene expression in control (r2=0.73) and cediranib
treated (r2=0.68) animals respectively. r2 values are calculated
from genes detected in both replicates. Gene expression is given as
RPKM.
(TIFF)
Figure S3 RT-qPCR gene expression correspondence
between biological replicates. Scatterplot (A) represents
tumour (human) gene expression from control animals (r2=0.95)
and (B) corresponding host (mouse) gene expression (r2=0.88). r2
values are calculated from genes detected in both replicates. Gene
expression is given as –DCT.
(TIFF)
Figure S4 Changes in human and mouse gene detection
correspondence between RNA-Seq and RT-qPCR at
count thresholds ranging from one to 101 reads.
Correspondence at each threshold was calculated using the
Correspondence Score described in Materials and Methods. Data
for Human and Mouse Control_2 samples are shown.
(TIF)
Table S1 Calu6 xenograft mapping coverage statistics.
(XLSX)
Table S2 Calu6 xenograft transcript mapping statistics.
(XLSX)
Table S3 Calu6 xenograft protein coding transcript
coverage.
(XLSX)
Table S4 Correspondence between the proportion of
reads mapping to mouse and the experimentally
estimated species content of sample.
(XLSX)
Human Tumour Xenograft Profiling Using RNA-Seq
PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e66003
Table S5 RT-qPCR assay probe identifiers and -DCT
values across control and treated calu6 xenograft
samples.
(XLSX)
Table S6 Correspondence in gene expression quantifi-
cation and detection between RNA-Seq and RT-qPCR.
(XLSX)
Table S7 RT-qPCR DCT values for all six treated and
eight control calu6 xenograft samples.
(XLSX)
Table S8 Correspondence in gene expression quantifi-
cation between RNA-Seq and Affymetrix Human U133
Plus 2.0/Mouse 430 2.0 gene arrays.
(XLSX)
Table S9 LoVo xenograft mapping coverage statistics.
(XLSX)
Table S10 Read counts across human transcripts in
control and treated calu6 xenograft samples.
(XLSX)
Table S11 Read counts across mouse transcripts in
control and treated calu6 xenograft samples.
(XLSX)
Table S12 Fold changes and significance across human
transcripts between control and treated calu6 xenograft
samples.
(XLSX)
Table S13 Fold changes and significance across mouse
transcripts between control and treated calu6 xenograft
samples.
(XLSX)
Table S14 Human and mouse 18S rRNA ARMS assay
primer and probe sequences.
(XLSX)
Table S15 Calu6 xenograft splice junction read statis-
tic.
(XLSX)
Acknowledgments
The authors would like to thank The Liverpool Centre for Genomics for
performing the sequencing, and Dr John Kenny at University of Liverpool
for providing the sequencing protocol details.
Author Contributions
Conceived and designed the experiments: SJP THC JRD NJG STB.
Performed the experiments: JRB MF SJP SR SLW HB OD NRS.
Analyzed the data: JRB MF MW. Wrote the paper: JRB STB.
References
1. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, et al. (2005)
cediranib: a highly potent, orally bioavailable, vascular endothelial growth factor
receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:
4389–4400
2. Creighton CJ, Kuick R, Misek DE, Rickman DS, Brichory FM, et al. (2003)
Profiling of pathway-specific changes in gene expression following growth of
human cancer cell lines transplanted into mice. Genome Biol 4: R46.
3. Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory FM, et al.
(2005) Analysis of tumor-host interactions by gene expression profiling of lung
adenocarcinoma xenografts identifies genes involved in tumor formation. Mol
Cancer Res 3: 119–129
4. Harrell JC, Dye WW, Harvell DM, Sartorius CA, Horwitz KB (2008)
Contaminating cells alter gene signatures in whole organ versus laser capture
microdissected tumors: a comparison of experimental breast cancers and their
lymph node metastases. Clin Exp Metastasis, 25: 81–88
5. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke R (2006) Effects of oestrogen
on gene expression in epithelium and stroma of normal human breast tissue.
Endocr Relat Cancer, 13: 617–628
6. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, et al. (2011) Upregulated
stromal EGFR and vascular remodeling in mouse xenograft models of
angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest
121: 1313–1328
7. Lu P, Nakorchevskiy A, Marcotte EM (2003) Expression deconvolution: A
reinterpretation of DNA microarray data reveals dynamic changes in cell
populations. Proc. Nat. Acad. Sci. USA. 100:10370–10375
8. Lahdesmaki H, Shmulevich L, Dunmire V, Yli-Harja O, Zhang W (2005) In
silico microdissection of microarray data from heterogeneous cell populations.
BMC Bioinformatics 6:54
9. Venet D, Pecasse F, Maenhaut C, Bersini H (2001) Separation of samples into
their constituents using gene expression data. Bioinformatics 17: S279–S287
10. Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman L, et al.
(2004) In silico dissection of cell-type-associated patterns of gene expression in
prostate cancer. Proc Nat Acad Sci USA 101: 615–620.
11. Ghosh D (2004) Mixture models for assessing differential expression in complex
tissues using microarray data. Bioinformatics 20: 1663–1669
12. Gosink MM, Petrie HT, Tsinoremas NF (2007) Electronically subtracting
expression patterns from a mixed cell population. Bioinformatics 23: 3328–3334
13. Clarke J, Seo P, Clarke B (2010) Statistical expression deconvolution from mixed
tissue samples. Bioinformatics 26: 1043–1049.
14. Naef F, Huelsken J (2005) Cell-type-specific transcriptomics in chimeric models
using transcriptome-based masks. Nucl Acids Res 33: e111
15. Park ES, Kim SJ, Kim SW, Yoon S-L, Leem S-H, et al. (2011) Cross-species
hybridization of microarrays for studying tumor transcriptome of brain
metastasis. Proc Natl Acad Sci USA 108: 17456–17461
16. Fu GCL, Lin WC (2012) Identification of gene-orientated exon orthology
between human and mouse. BMC Genomics 13 (Suppl 1): S10
17. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, et al. (2002)
Initial sequencing and comparative analysis of the mouse genome. Nature 420:
520–562
18. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for
transcriptomics. Nat Rev Genetics 10: 57–63
19. Farren M, Weston S, Brown H, Broadbent N, Powell S, et al. (2012) Expression
of stromal genes associated with the angiogenic response are not differentiated
between human tumour xenografts with divergent vascular morphologies.
Angiogenesis 15: 555–568
20. Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S (2011) Assessing the
activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1
and members of the structurally related PDGFR family. Mol Cancer Ther 10:
861–873.
21. Smith NR, James NH, Oakley I, Wainwright A, Copley C, et al. (2007) Acute
pharmacodynamic and antivascular effects of the vascular endothelial growth
factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.
Mol Cancer Ther 6: 2198–2208.
22. Anders S, Huber W (2010) Differential expression analysis for sequence count
data. Genome Biology, 11: R106
23. Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, et al. (2012)
Identification and angiogenic role of the novel tumor endothelial marker
CLEC14A. Oncogene 31:293–305
24. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. (2007)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+
myeloid cells. Nat Biotechnol 25: 911–920
25. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, et al. (2007) Bv8 regulates
myeloid-cell-dependent tumour angiogenesis. Nature 450: 825–831.
26. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, et al. (2009) G-CSF-
initiated myeloid cell mobilization and angiogenesis mediate tumor refractori-
ness to anti-VEGF therapy in mouse models. PNAS 106: 6742–6747.
27. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, et al. (2012) A
CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell
150: 165–178
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL (2005) Gene
set enrichment analysis: A knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci USA 102: 15545–15550
29. The Gene Ontology Consortium (2000) Gene ontology: tool for the unification
of biology. Nat Genet 25: 25–29
30. Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, et al. (2012) Xenome-a
tool for classifying reads from xenograft samples. Bioinformatics 28: i172–i178
31. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome Biol
10: R25
32. Smith NR, Baker D, James N, Ratcliffe K, Ashton S, et al. (2010) Vascular
Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 are localised
primarily to vasculature in human primary solid cancers. Clin Canc Res 16:
3548–3561
Human Tumour Xenograft Profiling Using RNA-Seq
PLOS ONE | www.plosone.org 11 June 2013 | Volume 8 | Issue 6 | e66003
33. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy-analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 20: 307–315
34. Okoniewski MJ, Yates T, Dibben S, Miller CJ (2007) An annotation
infrastructure for the analysis and interpretation of Affymetrix exon array data.
Genome Biology 8: R79
35. Pepke S, Wold B, Mortazavi A (2009) Computation for ChIP-seq and RNA-seq
studies. Nature Methods 6, S22–S32
36. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and
quantifying mammalian transcriptomes by RNA-Seq. Nature Methods 5: 621–
628
37. Koehler R, Issac H, Cloonan N, Grimmond SM (2011) The uniqueome: a
mappability resource for short-tag sequencing. Bioinformatics 27: 272–274
38. Matthews BW (1975) Comparison of the predicted and observed secondary
structure of T4 phage lysozyme. Biochim Biophys Acta 405: 442–451.
39. Bradford JR, Hey Y, Yates T, Li Y, Pepper SD, et al. (2010) A comparison of
massively parallel nucleotide sequencing with oligonucleotide microarrays for
global transcription profiling. BMC Genomics 11: 282
Human Tumour Xenograft Profiling Using RNA-Seq
PLOS ONE | www.plosone.org 12 June 2013 | Volume 8 | Issue 6 | e66003
